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Liver fibrosis is a wound-healing process in response to repeated and chronic injury
to hepatocytes and/or cholangiocytes. Ongoing hepatocyte apoptosis or necrosis lead
to increase in ROS production and decrease in antioxidant activity, which recruits
inflammatory cells from the blood and activate hepatic stellate cells (HSCs) changing
to myofibroblasts. Injury to cholangiocytes also recruits inflammatory cells to the liver
and activates portal fibroblasts in the portal area, which release molecules to activate
and amplify cholangiocytes. No matter what origin of myofibroblasts, either HSCs
or portal fibroblasts, they share similar characteristics, including being positive for
α-smooth muscle actin and producing extracellular matrix. Based on the extensive
pathogenesis knowledge of liver fibrosis, therapeutic strategies have been designed
to target each step of this process, including hepatocyte apoptosis, cholangiocyte
proliferation, inflammation, and activation of myofibroblasts to deposit extracellular
matrix, yet the current therapies are still in early-phase clinical development. There is
an urgent need to translate the molecular mechanism of liver fibrosis to effective and
potent reagents or therapies in human.
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INTRODUCTION
Liver fibrosis is a wound-healing process of the liver in response to repeated and chronic liver injury
with distinct etiologies, such as infectious diseases (e.g., viral hepatitis), metabolic derangements
(non-alcoholic steatohepatitis), exposure to chemicals (e.g., alcohol liver diseases), or autoimmune
diseases (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis).
The identical morphology characteristics of liver fibrosis are the quantitative and qualitative
deposition of extracellular matrix which is produced by myofibroblasts. Myofibroblasts are
absent from the healthy liver, accumulate in the injured liver and serve as the principle effector
cells of fibrogenesis. Although control and clearance of the underlying causative etiology (e.g.,
virus eradication or alcohol absence) can slow down fibrosis progression and lead to fibrosis
regression, the extensive knowledge on the mechanism leading to liver fibrosis through hepatocyte
injury, chaolangiocyte proliferation, inflammation, and activation of myofibroblasts to deposit
extracellular matrix has not been translated into effective and potent reagents or therapies in human
so far (Hauff et al., 2015). In this review we would like to summarize the current knowledge of
targeting each step of the pathologenesis process to relieve liver fibrosis.
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INJURY-INDUCED HEPATOCYTE
APOPTOSIS
Chronic liver injury, including viral hepatitis and nonalcoholic
steatohepatitis (NASH), is typically associated with apoptosis
of hepatocytes, which recruit inflammatory cells and promote
liver fibrosis. Inactivation of Caspase 1, Caspase 2, or Caspase
3 protects hepatocytes against apoptosis, reduces cytokines
involved in inflammatory signaling, and ameliorates fibrogenesis
in diet-induced NASH models (Dixon et al., 2012; Machado
et al., 2014; Thapaliya et al., 2014). The pan-caspase inhibitor,
VX-166 could reduce oxidative stress, inflammation, HSC
activation, and extracellular matrix deposition in non-alcoholic
steatohepatis mouse (Witek et al., 2009; Anstee et al., 2010).
Another pan-caspase inhibitor, IDN-6556, also attenuates hepatic
inflammation, hepatic stellate cells (HSCs) activation, and liver
fibrosis in murine bile duct ligation (BDL) model (Canbay
et al., 2004) and steatohepatitis models (Barreyro et al.,
2015). In a clinical study, oral administration of IDN-6556
can reduce aminotransferase activity in chronic hepatitis C
patients (Pockros et al., 2007). Now, IDN-6556 has been
completed the investigation in randomized, double-blind phase
II studies for the treatment of Non-alcoholic fatty liver disease
(NAFLD), hepatitis C virus (HCV), and cirrhosis (Table 1).
Interestingly, co-administration of an antioxidant (lithospermate
B) and caspase inhibitor (nivocasan) can suppress oxidative
stress and hepatocyte apoptosis, resulting in a combined effect
on reversal of liver fibrosis in rats (Kim do et al., 2013),
which provides a better basis for effective therapy to liver
fibrosis.
INJURY-INDUCED CHOLANGIOCYTE
PROLIFERATION
Injury to cholangiocytes recruits inflammatory cells from the
blood and activates portal fibroblasts in the portal area, which
release molecules to activate and amplify the proliferation
biliary progenitor cells (activated cholangiocytes). In BDL
cholestatic injury model, bile ductular cells and fibroblastic-
appearing cells in the portal area express Hedgehog (Hh)
ligands, receptor, and/or target genes (Omenetti et al., 2007).
Furthermore, myofibroblasts release soluble Hh ligands that
stimulate cholangiocytes to produce Cxcl16 and recruit NKT
cells (Omenetti et al., 2009). Hh signaling antagonist GDC-0449
could inhibit liver myofibroblasts and progenitors, relieve liver
fibrosis, and even promotes regression of HCC in phospholipid
flippase (Mdr2) knockout mice (Philips et al., 2011). Integrin
αvβ6, which is another molecular absent in normal liver,
promotes proliferation of cholangiocytes and plays functional
roles in activating latent TGF-β1. Cholangiocytes exhibit marked
increased expression of αvβ6 integrin in thioacetamide (TAA)-
and BDL-induced fibrosis, and in human HCV fibrosis and
end-stage cirrhosis (Wang et al., 2007; Popov et al., 2008).
Inhibition of αvβ6 could attenuate collagen deposition, improve
liver function, and retard progression of biliary fibrosis in
mouse orthotopic liver transplantation model (Chen et al., 2013).
Impressively, a single dose of integrin αvβ6 inhibitor exhibits
TABLE 1 | Liver injury animal model findings with potential antifibrotic
effects.
Targets Mechanism Intervention Animal model
Injured
hepatocytes
Pan-caspase
inhibitor
VX-166 NAFLD
Pan-caspase
inhibitor
IDN-6556 BDL; NAFLD
Cholangiocyte Hh signaling
antagonist
GDC-0449 Mdr2-/-
Proliferation Integrin αvβ6
antagonist
Integrin αvβ6 antibody Ischemia-related
biliary fibrosis after
orthotopic liver
transplantation
Integrin αvβ6
antagonist
EMD527040 Mdr2-/-
Recruitment
of
P2X7
antagonist
A438079 CCl4;
acetaminophen
inflammatory
cells
CXCR2-FPR1 BOC-1 and DF2156a acetaminophen
HMGB1-
mediated
inflammatory
signaling
E5564 ischemia and
reperfusion
TLR9 COV08-0064 acetaminophen
IL17A IL17A antibody S. japonicum;
NASH
Nox/ROS
signaling
NOX1/NOX4
inhibitor
GKT137831 CCl4; BDL;
Fast-food Diet
antioxidant Anthocyanin Acetaminophen;
BDL; Alcohol
antioxidant β-Lapachone alcoholic fatty liver
disease
Hh signaling Progenitor
response
CCl4; MCD; DDC
Myofibroblasts
Activation
TGF-β
antibody
1D11 TAA
CTGF siRNA NA CCl4
Hh signaling
antagonist
GDC-0449 BDL; NASH
Hh signaling
antagonist
CYA BDL
S1P
antagonist
suramin CCl4; BDL; TAA
LOXL2
antibody
AB0023 CCl4
MCD, methionine-choline deficient diet; DDC, 3,5,-diethoxycarbonyl-1,4-dihydrocollidine
diet; TAA, thioacetamide.
antifibrogenic and profibrolytic effects (Popov et al., 2008), which
might serve as a target for anti-fibrosis therapy.
DAMAGED PARENCHYMAL CELLS
RECRUIT INFLAMMATORY CELLS TO THE
LIVER
Endogenous damage-associated molecular patterns (DAMPS)
released or leaked from dying hepatocytes act as danger
signals recruiting immune cells to the site of injury and
initiating inflammatory response (Kubes and Mehal, 2012).
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A large variety DAMPS have been identified, including
nucleic acids, proteins [for example, high mobility group
box-1 (HMGB1)], and cellular components [for example,
adenosine triphosphate, (ATP)]. It has been shown that ATP
released from necrotic hepatocytes generates an inflammatory
microenvironment attracting neutrophils to the liver sinusoids
via P2X7R, a sensor monitoring the release of ATP at
inflammation sites, in a murine hepatic necrosis model by
localized thermal injury (McDonald et al., 2010). Neutrophil
recruitment is significantly reduced in response to tissue injury
either by blocking P2X7 receptor or by genetic deficiency of
P2x7r−/− in mice (McDonald et al., 2010). The specific P2X7
antagonist, A438079, could markedly reduce acetaminophen-
induced necrosis (Hoque et al., 2012) and alive CCl4-
induced liver inflammation and injury (Huang et al., 2014).
Although ATP signals initiate neutrophil adhesion to liver
sinusoid, it is the chemokines and mitochondrial contain
DAMPs, including formyl-peptide receptor 1 (FPR1), that
guide and direct neutrophils migration through health tissue
toward injured foci (McDonald et al., 2010). CXCR2-FPR1
antagonism can block neutrophil infiltration and hepatotoxicity
in acetaminophen-induced liver injury (Marques et al., 2012).
These findings suggest blocking P2X7R and/or CXCR2-FPR1
could be a promising therapeutic approach to control liver
inflammation.
The HMGB1 is a nonhistone nuclear protein that facilitates
regulatory proteins binding to DNA. HGMB1 is constitutively
expressed by most of the cells and will be released under injury
and death. HGMB1 is highly induced during liver injury (Ge
et al., 2014) and contributes to inflammation through binding
to TLR4 (McDonald et al., 2015). It is proposed that HMGB1
may not have a direct proinflammatory effect but acts with other
proinflammatory mediators such as lipopolysaccharide (LPS;
Bianchi, 2009). LPS, a cell-wall component of Gram-negative
bacteria, is among the strongest known inducers of inflammation.
It has been shown that patients suffered from chronic liver
disease had altered gut microbiota and intestinal permeability
resulting in releasing bacterial endotoxins, including LPS, to
the circulation (Cesaro et al., 2011; Hartmann et al., 2013;
Brenner et al., 2015). The leaky gut further induces and
stimulates the progression of liver inflammation in addition to
the direct injury. As the receptor of HMGB1 and LPS, TLR4
increases TGF-β1 production by Kupffer cells and activates HSCs
promoting liver fibrosis (Federico et al., 2015). An inhibitor
of TLR4, Eritoran tetrasodium (E5564), can prevent the gut
barrier permeability and reduce liver damage by lower IL-6
level and less NF-κB activation in hemorrhagic shock mice with
resuscitation (Korff et al., 2013). Pharmacological inhibition
of TLR4 by Eritoran tetrasodium ameliorates liver injury
through blocking HMGB1-mediated inflammatory signaling in
ischemia and reperfusion mice (McDonald et al., 2015) In
addition, both bacterial DNA and mitochondrial DNA and
nuclear DNA released by damaged hepatocyte can activate TLR9
and induce a number of cellular immune responses (Kubes
and Mehal, 2012). A specific antagonist of TLR9, COV08-
0064, could limit the sterile inflammation in rat and mouse
models of acute liver injury and acute pancratitis (Hoque
et al., 2013). So, the antagonists of TLRs provide us new
options of combination drug therapy for controlling liver
inflammation.
Th17 cells are derived from Naive CD4+ T cells, which are
rare in normal liver, but accumulate in the portal areas around
bile ducts in chronic liver diseases (Wang et al., 2011; Oo et al.,
2012). Th17 cells express CCL20, a ligand for CCR6. Using
cytokine-treated human cholangiocytes, CCL20 could induce
CCR6-dependent migration of Th17 cells (Oo et al., 2012), which
might be one of themechanisms for inflammatory cells recruiting
to the liver. IL17 expressed by Th17 cells activates Kupffer cells
to produce proinflammatory and profibrotic cytokines for
fibrogenesis, and directly increase the expression of collagen,
α-SMA, TGF-β in HSCs (Meng et al., 2012). IL-17 monoclonal
antibody ameliorates hepatic granulomatous inflammation
through downregulation of inflammatory cytokines and
recruitment of neutrophils in mouse infected with Schistosoma
japonicum (S. japonicum) larvae (Zhang et al., 2012). And
neutralization of IL-17 in NASH mice ameliorates LPS-induced
inflammatory cell infiltrating into the liver (Tang et al., 2011).
Antibodies against IL17A has been used in phase II-III clinical
trials to establish their therapeutic effects in autoimmune diseases
(Schuppan and Kim, 2013), yet no information is available for
clinical trials on liver fibrosis now.
APOPTOTIC HEPATOCYTES ACTIVATE
HSCs THROUGH Nox/ROS SIGNALING
Ongoing hepatocyte apoptosis or necrosis leads to increase in
ROS production and facilitates HSCs activation and migration,
which is one of the characteristics of chronic liver disease that
triggers liver fibrogenesis. Nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (NOX) produces reactive oxygen
species (ROS) via transferring electron from nicotinamide
adenine dinucleotide phosphate to molecular oxygen, which is
different from other redox enzymes that produce superoxide
as a byproduct. The mammalian NOX family is composed of
seven isoforms: NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1,
and DUOX2, which are distinctively expressed in specific
cell types in the liver. HSCs express three Nox isoforms,
Nox1, Nox2, Nox 3 (Paik et al., 2014). HSCs from p47phox-
deficient mice (without a regulatory component of NOX) fail
to generate ROS in response to angiotensin II, platelet derived
growth factor (PDGF), leptin, or apoptotic bodies, and p47phox-
deficient mice demonstrate reduced liver fibrosis after BDL
or the hepatotoxin CCl4. (De Minicis and Brenner, 2007; De
Minicis et al., 2010). Since NOX1 and NOX4 are expressed
in α-SMA positive activated HSCs, GKT137831, a potent dual
NOX1/NOX4 inhibitor, attenuates ROS production and inhibits
activation of HSCs (Paik et al., 2014). In vivo experiments
show that GKT137831 could suppress ROS production, liver
inflammation and ameliorate CCl4-, BDL-, and Fast-Food Diet-
induced liver fibrosis (Aoyama et al., 2012; Jiang et al., 2012;
Bettaieb et al., 2015).
Although hepatocyts express many isoforms of Nox,
the development of steatosis by a high-fat, methionine and
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choline-deficient (MCD) diet is independent from Nox
activation in hepatocytes. In steatosis, the majority of ROS
production may derive from hepatocellular lipid deposition
and subsequent peroxidation. Anthocyanin, a plant-derived
antioxidant, could reduce oxidative stress, relieve hepatic
inflammation, and protect hepatocytes against injury, indicating
its potential antifibrotic effects (Choi et al., 2009; Hou et al., 2010;
Donepudi et al., 2012). Administration of beta-Lapachone (3,4-
dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione), a
natural compound extracted from the bark of the lapacho tree
(Tabebuia avellanedae), upregulates apoB100 synthesis and lipid
mobilization via modulation of NAD(+)/NADH ratio to activate
AMPK signaling (Shin et al., 2014). Although vitamin E may
reduce the liver oxidative stress and the fibrosis development,
administration vitamin E supplementation does not consistently
result in protection from liver injury. Multicenter, long-term
clinical trials are still needed to evaluate the role of antioxidants
in NASH.
DYING HEPATOCYTES ACTIVATE HEPATIC
PROGENITORS THROUGH Hh SIGNALING
Hh signal released by dying hepatocyte could activate the
compensatory outgrowth of hepatic progenitors, which are
involved in liver regeneration (Jung et al., 2010). As a
Hh target, osteopontin is highly expressed in fibrotic liver
tissue and influences the function of hepatic progenitors
(Coombes et al., 2015). And neutralization of osteopontin
could suppress progenitor cell response and attenuate liver
fibrosis in CCl4, methionine-choline deficient diet (MCD)
and 3,5,-diethoxycarbonyl-1,4-dihydrocollidine diet (DDC)mice
(Coombes et al., 2015).
TREATING LIVER FIBROSIS BY
TARGETING MYOFIBROBLAST
ACTIVATION
Chronic inflammation is linked to liver fibrosis through
activating the fibrogenetic effector cells, HSCs, portal fibroblasts,
bone marrow-derived fibrocytes, and mesenchymal stem
cells. HSCs are the major source of hepatic myofibroblasts
during development of liver fibrosis under different etiologies
(Mederacke et al., 2013). Portal fibroblasts play a less role in
the pathogenesis of liver fibrosis than HSCs because they were
implicated to pathogenesis of cholestatic liver injury (Wells,
2014). Fibrocytes with dual characteristics of fibroblasts and
hematopoietic cells migrate to the injured liver in response
to BDL and CCl4-damaged liver and comprise about 5% of
the collagen type I expressing myofibroblasts (Kisseleva et al.,
2006; Scholten et al., 2011). Bone marrow-derived mesenchymal
stem cells could also be recruited to the injured liver and
facilitate fibrogenesis (Russo et al., 2006; Li et al., 2009).
Although epithelial-mesenchymal transition of hepatocytes
and cholangiocytes has been reported to be another origin of
myofibroblasts (Omenetti et al., 2007; Zeisberg et al., 2007; Nitta
et al., 2008; Syn et al., 2009), recent studies using cell fatemapping
detect only minimal or no contribution of EMT by hepatocytes,
cholangiocytes, or hepatic progenitors to myofibroblasts
(Scholten et al., 2010; Taura et al., 2010; Chu et al., 2011). And,
although endothelial cell injury and neovascularization play a
critical role in liver fibrosis, the transition of endothelial cells to
mesenchymal cells (EndMT) giving rise myofibroblasts is still
not definitively resolved. So, anti-fibrotic therapy targeting the
myofibroblast activation process of HSCs, portal fibroblasts,
fibrocytes, and mesenchymal stem cells might be more useful
than blocking EMT or EndMT.
After engulfment of apoptotic bodies, Kupffer cells are
stimulated to produce TGF-β1 (Szondy et al., 2003), which is a
potent cytokine to activate HSCs, fibrocytes, and mesenchymal
stem cells into myofibroblasts (Kisseleva et al., 2006; Li et al.,
2009; Meindl-Beinker et al., 2012). Although TGF-β is one of the
most potent stimuli of extracellular matrix synthesis, suppressing
its expression remains a major challenge of antifibrotic therapy,
since systemic blocking of TGF-β1 can provoke inflammation
and increase the risk of neoplasia. Neutralization TGF-β in
animal models inhibits liver fibrosis and reduces the risk
in developing cholangiocarcinoma (Fan et al., 2013; Ling
et al., 2013). Fresolimumab (GC1008) is a human anti-TGF-
β1 monoclonal antibody that neutralizes all isoform of TGF-
β. In patients with advanced malignant melanoma and renal
cell carcinoma, fresolimumab demonstrated acceptable safety
and preliminary evidence of antitumor activity (Trachtman
et al., 2011; Morris et al., 2014; Lacouture et al., 2015).
Using radio-labeled (89)Zr-conjugated fresolimumab for PET
to analyze TGF-β expression, GC1008 accumulated in primary
tumors and metastases in a manner similar to IgG, and (89)
Zr-fresolimumab uptake is seen in sites of tumor ulceration and
in scar tissue, where TGF-β is highly active (Oude Munnink
et al., 2011). Although there is phase II clinical trial ongoing of
fresolimumab, optimal strategies are still needed to restrict it to
the fibrotic milieu. TGF-β transduces its signal to target genes
through the ALK5 ser/thr kinase receptor. GW6604 (2-phenyl-4-
(3-pyridin-2-yl-1H-pyrazol-4-yl)-pyridine), an ALK5 inhibitor,
inhibits the transcription and deposition of extracellular matrix
and improves the deterioration of liver function in mice (de
Gouville et al., 2005). Yet, considering of the pleiotropic effects
of TGF-β, treatment with an ALK5 inhibitor should be carefully
examined to avoid the unwanted effects (de Gouville and Huet,
2006).
As a TGF-β target gene, CTGF is considered as a central
mediator which is specific for promoting fibrogenensis. It has
been reported that inhibition of CTGF expression by siRNA
prevents CCl4-induced liver fibrosis and can induce regression
of liver fibrosis (Hao et al., 2014). A human monoclonal antibody
to CTGF, FG-3019, has been investigated in various animal
models (e.g., liver fibrosis, diabetes, pulmonary fibrosis) and
demonstrated a reduction and regression of fibrogenesis. FG-
3019 binds to the second domain of human CTGF and is
currently under phase II drug investigation for the treatment of
liver fibrosis (Lipson et al., 2012; Hauff et al., 2015).
Platelet-derived growth factor (PDGF) is the most potent
mitogen for HSC. Imatinib mesylate, a clinically used PDGF
receptor tyrpsine kinase inhibitor, attenuates liver fibrosis at
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early stages, but does not prevent advanced liver fibrosis
in animal experiments (Yoshiji et al., 2005; Neef et al.,
2006). PTPRO (protein tyrosine phosphatase, receptor type
O) shRNA significantly neutralized PDGF-BB-induced HSC
proliferation and myofibroblast marker expression through
downregulated phosphorylation of extracellular signal-regulated
kinase (ERK) and AKT. PTPRO knockout mice [PTPRO(-/-)]
have attenuated liver injury, release of inflammatory factors,
tissue remodeling, and liver fibrosis in fibrogenesis induced by
BDL or carbon tetrachloride (CCl4) administration (Zhang et al.,
2015).
Not only does Hh signaling participate in cholangiocyte-
chemokine secretion and progenitor response, but also it
is involved in liver injury and inflammation after ischemia
reperfusion and BDL (Pratap et al., 2010, 2011). Pharmacological
inhibition of Hedgehog signaling by vismodegib (GDC-0449)
and CYA could attenuate BDL-induced liver fibrosis (Pratap
et al., 2012). And vismodegib relieves hepatic inflammation and
liver fibrosis in a mouse nutrient excess model of NASH (Hirsova
et al., 2013).
Sphingosine 1-phosphate (S1P) is a multifunctional mediator
with increased synthesis in the liver following acute and chronic
liver injury (Li et al., 2009, 2011), while its concentration
remains a relative low level in the bone marrow. This S1P
gradient between liver and bone marrow drives the recruitment
of bone marrow-derived mesenchymal stem cells into the
circulation and into the liver afterwards. Selective S1P receptor
antagonist, suramin, has anti-fibrotic effects in CCl4 and
BDL liver fibrosis (Li et al., 2009) and hepatoprotective and
antitumor activities in TAA-induced liver injury (Tayel et al.,
2014).
Inhibitors of receptor tyrosine kinase and Ser/Thr kinase also
demonstrate some anti-fibrosis effects. Multitargeted receptor
tyrosine kinase inhibitor Sorafenib, which has been approved
for the treatment of advanced renal cell carcinoma and
hepatocellular carcinoma (HCC), and Sunitinib, can improve
TABLE 2 | Ongoing clinical studies of antifibrotic drugs.
Targets Mechanism Intervention NCT no. Disease
condition
Phase Status
Injured hepatocytes Pan-caspase
inhibitor
IDN 6556 NCT02230683 Liver cirrhosis with
portal
hypertension
Phase 2 Complete
Pan-caspase
inhibitor
IDN 6556 NCT02077374 NAFLD Phase 2 Complete
Pan-caspase
inhibitor
IDN 6556 NCT00088140 Chronic HCV Phase 2 Complete
Pan-caspase
inhibitor
IDN 6556 NCT02230670 Liver cirrhosis Phase 2 Active, not recruiting
Pan-caspase
inhibitor
IDN 6556 NCT01912404 Severe AH Phase 2 Terminated
Cholangiocyte proliferation hedgehog inhibitor LDE225 NCT02151864 HCC and liver
cirrhosis
Phase 1 Recruiting
Nox/ROS Anti-oxidant Vitamin E NCT01792115 NAFLD Phase 2 Recruiting
Signaling Anti-oxidant Anthocyanin NCT01940263 NAFLD Phase 0 Complete
Myofibroblasts CTGF antibody FG-3019 NCT01217632 Liver Fibrosis Due
to HBV
Phase 2 Active, not recruiting
LOXL antibody Simtuzumab NCT01452308 Liver Fibrosis Phase 2 Complete
LOXL antibody Simtuzumab NCT01672879 NASH Phase 2 Active, not recruiting
LOXL antibody Simtuzumab NCT01672853 PSC Phase 2 Active, not recruiting
Mesenchymal stem cells Umbilical cord
MSCs
Transplantation NCT01724398 Liver failure Phase 1 Unknown
Phase 2
Umbilical cord
MSCs
Transplantation NCT01218464 Liver failure Phase 1 Unknown
Phase 2
Autologous MSCs Transplantation NCT01741090 Alcoholic Liver
Cirrhosis
Phase 2 Unknown
Umbilical cord
MSCs
Bone marrow
MSCs
Transplantation NCT01844063 Liver failure Phase 1
Phase 2
recruiting
Autologous MSCs Transplantation NCT00420134 Liver failure,
cirrhosis
Phase 1 Complete
Phase 2
Autologous MSCs Transplantation NCT00956891 Liver failure Phase 1 Complete
Phase 2
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experimental hepatic fibrosis, inflammation, and angiogenesis
(Tugues et al., 2007; Mejias et al., 2009). SiRNA of transient
receptor potential melastatin 7 (TRPM7), a non-selective cation
channel with protein serine/threonine kinase activity, attenuates
TGF-β1-induced expression of myofibroblast markers, increases
the ratio of MMPs/TIMPs, and decrease the phosphorylation of
Smad2 and Smad3 associated collagen production (Fang et al.,
2013, 2014). Hepatic nuclear factor kappa B (NF-κB)-inducing
kinase (NIK), a Ser/Thr kinase, which is increased in injured
livers in both mice and humans, induces hepatocyte injury,
activates bone marrow-derived macrophages, and leads to liver
fibrosis, and this might serve as a candidate for liver fibrosis
therapy (Shen et al., 2014).
No matter what the origin of myofibroblasts is, the common
feature of them is expressing extracellular matrix. In liver
fibrosis, type I collagen is the most prominent increased
components of extracellular matrix. The cross-linking of type
I collagen is also increased, which is modulated by the
matrix enzyme lysyl oxidase-like-2 (LOXL2). Although blocking
collagens have unwanted off-target effects, inhibition of LOXL2
by a monoclonal antibody (AB0023) reduces the production of
cytokines, attenuates TGF-β signaling, and inhibits the activate
fibroblasts (Barry-Hamilton et al., 2010). Similar to AB0023,
another humanizedmonoclonal LOXL2 antibody (GS-6624) is in
randomized, double blind, phase II clinical trials to treat NASH
and PSC (Schuppan and Kim, 2013).
TRANSPLANTATION OF MESENCHYMAL
STEM CELLS TO RELIEVE LIVER FIBROSIS
Mesenchymal stem cells, which reside in various tissue, such as
bone marrow, umbilical cord blood, adipose tissue and others,
can differentiate into multiple cell lineages in vitro, including
hepatocyte (Ye et al., 2015). Yet, few engraft human cells could be
found in the liver after transplantation of human mesenchymal
stem cells into the sublethally irradiated NOD/SCID mice
exposed to acute or chronic CCl4 injury (di Bonzo et al., 2008).
Although endogenousmesenchymal stem cells contribute to liver
fibrogenesis during liver injury as described previously, recent
studies have demonstrated that exogenous transplantation of
mesenchymal stem cells have immunomodulation, inflammation
suppression and antifibrogenic effects (Lin et al., 2011; Wang
et al., 2014; Christ et al., 2015). Many clinical investigations on
the safety and efficacy of mesenchymal stem cells for treatment
of liver failure and liver cirrhosis are under phase I and phase II
studies (Table 2).
CONCLUSION
Currently, there are many potential antifibrotic targets obtained
from animal experiments (Table 1), yet most of the therapies
are still in preclinical evaluation stages (Table 2). Since both
animal experiments and clinical studies have revealed that liver
fibrosis, even early cirrhosis, is reversible, treating patients
by combined therapies on underline etiology and fibrosis
simultaneously might expedite the regression of liver fibrosis
and promote liver regeneration. In the circumstance that the
underline etiology of liver fibrosis could not be eradicated,
therapies on liver fibrosis might help restrict the disease
progression to cirrhosis and reduce the risk of cirrhosis
related complication. In the future, the elucidation of the
molecular steps of regression of liver fibrosis might provide new
preventive and therapeutic strategies for fibrosis even cirrhosis
patients.
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